Publications by authors named "Robbin Itzler"

Claim this Profile
A
An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema.
Robbin Itzler, William R Lumry, John Sears, Julia Braverman, Yinglei Li

Orphanet J Rare Dis· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE-B trial 2 years after gene therapy.
Robbin Itzler, Tyler W Buckner, Frank W G Leebeek, Joel Miller, Michael Recht

Haemophilia· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The symptom experience of hereditary angioedema (HAE) patients beyond HAE attacks: literature review and clinician interviews.
Milenka Jean-Baptiste, Robbin Itzler, Subhransu Prusty, Dylan Supina, Mona L Martin

Orphanet J Rare Dis· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Severity of Acute Graft-versus-Host Disease and Associated Healthcare Resource Utilization, Cost, and Outcomes.
Nosha Farhadfar, Helen L Leather, Shu Wang, Nathan Burton, Vivian IrizarryGatell, Robbin Itzler

Transplant Cell Ther· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare utilization and cost of cancer-related care prior to allogeneic hematopoietic cell transplantation for hematologic malignancies in the US: a retrospective real-world analysis.
Machaon Bonafede, Elias Anaissie, Kristin Evans, Robbin Itzler

BMC Health Serv Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost, healthcare utilization, and outcomes of antibody-mediated rejection in kidney transplant recipients in the US.
Allyson Hart, David Zaun, Robbin Itzler, David Schladt, Ajay Israni

J Med Econ· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence, risk factors, and long-term outcomes associated with antibody-mediated rejection - The long-term Deterioration of Kidney Allograft Function (DeKAF) prospective cohort study.
Allyson Hart, David P Schladt, Arthur J Matas, Robbin Itzler, Ajay K Israni

Clin Transplant· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis by rotavirus gene 6 reverse transcriptase-polymerase chain reaction assay of rotavirus-positive gastroenteritis cases observed during the vaccination phase of the Rotavirus Efficacy and Safety Trial (REST).
David O Matson, Timo Vesikari, Penelope Dennehy, Michael D Dallas, Michelle G Goveia, Robbin F Itzler

Hum Vaccin Immunother· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling the durability of ZOSTAVAX® vaccine efficacy in people ≥60 years of age.
Xiaoming Li, Jane H Zhang, Robert F Betts, Vicki A Morrison, Ruifeng Xu, Robbin F Itzler

Vaccine· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of a pentavalent rotavirus vaccine in Japan.
Robbin Itzler, Megan A O'Brien, Kaoru Yamabe, Machiko Abe, Praveen Dhankhar

J Med Econ· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Burden of rotavirus hospitalisations in young children in three paediatric hospitals in the United States determined by active surveillance compared to standard indirect methods.
David O Matson, Mary Allen Staat, Parvin Azimi, Robbin Itzler, David I Bernstein

J Paediatr Child Health· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of a pentavalent human-bovine reassortant rotavirus vaccine for children ≤5 years of age in Taiwan.
Robbin F Itzler, Po Yen Chen, Christina Lac, Antoine C El Khoury, John R Cook

J Med Econ· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthy-days time equivalents for outcomes of acute rotavirus infections.
A Brett Hauber, Robbin Itzler, F Reed Johnson, Ateesha F Mohamed, Juan Marcos González

Vaccine· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1.
Jeroen P Jansen, Rachael Fleurence, Beth Devine, Robbin Itzler, Annabel Barrett

Value Health· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2.
David C Hoaglin, Neil Hawkins, Jeroen P Jansen, David A Scott, Robbin Itzler

Value Health· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen).
Penelope H Dennehy, Timo Vesikari, David O Matson, Robbin F Itzler, Michael J Dallas

Hum Vaccin· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pentavalent rotavirus vaccine in developing countries: safety and health care resource utilization.
Celia D C Christie, Newton D Duncan, Kirk A Thame, Matthew T Onorato, Hyacinth D Smith, Robbin F Itzler

Pediatrics· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5).
Robbin Itzler, Gary Koch, David O Matson, Leif Gothefors, Pierre Van Damme

BMC Pediatr· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses.
Michelle G Goveia, Leora Suprun, Robbin F Itzler, Richard McFetridge, Michael J Dallas

Pediatr Infect Dis J· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans.
Ronald R White, Greg Lenhart, Puneet K Singhal, Ralph P Insinga, Robbin F Itzler

Pharmacoeconomics· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe.
Timo Vesikari, Robbin Itzler, Aino Karvonen, Tiina Korhonen, Pierre Van Damme

Vaccine· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The burden of rotavirus hospitalizations among Medicaid and non-Medicaid children younger than 5 years old.
Liyuan Ma, Antoine C El Khoury, Robbin F Itzler

Am J Public Health· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health care utilization and cost burden of herpes zoster in a community population.
Barbara P Yawn, Robbin F Itzler, Peter C Wollan, James M Pellissier, Lina S Sy

Mayo Clin Proc· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico.
Atanacio Valencia-Mendoza, Stefano M Bertozzi, Juan-Pablo Gutierrez, Robbin Itzler

BMC Infect Dis· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries).
Timo Vesikari, Robbin Itzler, David O Matson, Mathuram Santosham, Celia D C Christie

Int J Infect Dis· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis